Skip to main content
Equibles

ZYXIQ · ZYNEX INC · Metrics

Track ZYXIQ — free

Use ZYXIQ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZYXIQ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
Rebalance outlook locked
Going-concern doubt — flagged Nov 17, 2025

Substantial doubt about the company's ability to continue as a going concern.

“Because certain elements of management's plans to mitigate the conditions that raised substantial doubt about the Company's ability to continue as a going concern are outside of the Company's control, including the ability to raise capital through an equity or other financing, those elements cannot be considered probable according to ASC 205-40, and therefore cannot be considered in the evaluation of mitigating factors. As a result, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date the unaudited condensed consolidated financial statements are issued.”
View the 10-Q filed Nov 17, 2025
Market Cap
$1.69M
Shares
30.39M

ZYXIQ metrics

43 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
—
Market cap
$1.69M

Price action

20 metrics
Price change (1W)
—
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Medical Distribution
Shares outstanding
30.39M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.0×
reciprocal yield 6,391.3%
P / book
—
FCF yield
-1,240.3%
TTM · current market cap
Buyback yield
291.7%
P / FCF
—
P / operating cash flow
—
Earnings yield
-4,368.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-17

Profitability

9 metrics
Gross margin
—
Operating margin
-62.8%
Trailing 12 months
Net margin
-68.4%
Gross profit (TTM)
$10.24M
Operating profit (TTM)
−$67.91M
Net income (TTM)
−$73.96M
Trailing 12 months
Diluted EPS (TTM)
$-2.43
FCF margin
-19.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.12

Growth

11 metrics
Revenue growth YoY
-73.3%
Year over year
Net income growth YoY
-1,901.6%
Revenue (TTM)
$108.20M
Trailing 12 months
EPS growth YoY
-2,128.6%
Shares change YoY
-5.5%
Year over year · fewer shares
Revenue CAGR (3Y)
+13.9%
Revenue CAGR (5Y)
+33.4%
EPS CAGR (3Y)
-41.1%
EPS CAGR (5Y)
-20.3%
FCF CAGR (3Y)
+24.2%
FCF CAGR (5Y)
+14.6%

Quality

14 metrics
Return on equity
—
Return on assets
-163.2%
Debt / equity
—
Current ratio
0.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$21.00M
Quick ratio
0.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$13.30M
Total assets
$45.32M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$20.57M
Capital expenditures (TTM)
$431,000
R&D (TTM)
—
SG&A (TTM)
$15.51M
Stock compensation (TTM)
$2.10M
R&D / revenue
—
Stock compensation / revenue
1.9%

Ownership (13F)

3 metrics
13F filers
1
13F filer change QoQ
0
Institutional ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 846475 CUSIP 98986M103 13F (30d) 1 filings 1 filers Visit website